Results: Compared with the normal liver function group, the plasma elimination half-life (T 1/2) of nalbuphine was increased by approximately 33% in the moderate/severe liver dysfunction group (2.66 h vs 3.54 h, P< 0.05), and the volume of distribution (V d) increased by approximately 85% (100.08 L vs 184.95 L, P< 0.05).
The pharmacokinetic parameters of nalbuphine were calculated by non-compartmental analysis (NCA) using Phoenix WinNonlin software. The plasma concentration of nalbuphine was determined using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). Venous blood samples were collected from each patient. During the induction of anesthesia, they received 15 mg of nalbuphine intravenously. Patients and Methods: Twenty-four patients were enrolled and divided into three cohorts based on liver function: normal liver function (n = 13), mild liver dysfunction (n = 5), and moderate/severe liver dysfunction (n = 6). Purpose: This study aimed to characterize the pharmacokinetics of nalbuphine in patients undergoing general anesthesia with varying degrees of liver dysfunction. Xiao-nan Gao, 1 Xu-yang Nie, 1 Jing-lin Gao, 1 Tian-fang Heng, 2 Yu-qi Zhang, 2 Li Hua, 1 Ya-qi Sun, 1 Zhang-ying Feng, 1 Ming-xia Wang, 1 Li Jia 2ġDepartment of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China 2Department of Anesthesiology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of ChinaĬorrespondence: Ming-xia Wang, Department of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University, 12 Jiankang Road, Shijiazhuang, People’s Republic of China, Tel +86 311-66696233, Email Li Jia, Department of Anesthesiology, The Fourth Hospital of Hebei Medical University, 12 Jiankang Road, Shijiazhuang, People’s Republic of China, Email